Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Treatment options for metastatic melanoma are limited. We conducted this phase II
trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating
factor (GM-CSF) in stages IIIc and IV disease.